> top > docs > PMC:3291650 > spans > 30770-32107 > annotations

PMC:3291650 / 30770-32107 JSONTXT

Annnotations TAB JSON ListView MergeView

test3

Id Subject Object Predicate Lexical cue
T11693 1147-1157 Negative_regulation denotes inhibitors

2_test

Id Subject Object Predicate Lexical cue
22396652-21431695-98461889 924-926 21431695 denotes 83

pmc-enju-pas

Id Subject Object Predicate Lexical cue
T12945 274-277 DT denotes the
T12944 270-273 CC denotes and
T12943 262-269 JJ denotes elderly
T12942 258-261 DT denotes the
T12941 256-257 -COMMA- denotes ,
T12940 249-256 NN denotes infants
T12939 246-248 IN denotes in
T12938 233-245 RB denotes particularly
T12937 231-232 -COMMA- denotes ,
T12936 222-231 NN denotes mortality
T12935 218-221 CC denotes and
T12934 208-217 NN denotes morbidity
T12933 203-207 JJ denotes high
T12932 200-202 TO denotes to
T12931 192-199 VB denotes leading
T12930 190-191 -COMMA- denotes ,
T12929 182-190 RB denotes annually
T12928 178-181 NN denotes IAV
T12927 175-177 IN denotes by
T12926 166-174 VB denotes infected
T12925 163-165 VB denotes is
T12924 152-162 NN denotes population
T12923 149-151 POS denotes 's
T12922 144-149 NN denotes world
T12921 141-143 IN denotes of
T12920 135-140 NN denotes fifth
T12919 133-134 DT denotes a
T12918 127-132 IN denotes About
T12917 116-125 NN denotes therapies
T12916 110-115 JJ denotes novel
T12915 103-109 IN denotes toward
T12914 98-102 NN denotes step
T12913 88-97 JJ denotes important
T12912 85-87 DT denotes an
T12911 82-84 VB denotes is
T12910 72-81 NN denotes responses
T12909 65-71 JJ denotes immune
T12908 55-64 JJ denotes antiviral
T12907 48-54 JJ denotes innate
T12906 45-47 IN denotes of
T12905 34-44 NN denotes activation
T12904 30-33 DT denotes the
T12903 18-29 VB denotes controlling
T12902 14-17 CC denotes and
T12901 0-13 VB denotes Understanding
T13110 1325-1336 NN denotes coronavirus
T13109 1320-1324 NN denotes SARS
T13108 1316-1319 CC denotes and
T13107 1312-1315 NN denotes RSV
T13106 1302-1311 VB denotes including
T13105 1291-1301 NN denotes infections
T13104 1285-1290 JJ denotes viral
T13103 1279-1284 JJ denotes other
T13102 1271-1278 IN denotes against
T13101 1264-1270 NN denotes battle
T13100 1260-1263 DT denotes the
T13099 1257-1259 IN denotes in
T13098 1248-1256 NN denotes interest
T13097 1245-1247 IN denotes of
T13096 1242-1244 VB denotes be
T13095 1236-1241 MD denotes might
T13094 1232-1235 NN denotes A20
T13093 1229-1231 IN denotes of
T13092 1219-1228 NN denotes targeting
T13091 1211-1218 JJ denotes similar
T13090 1209-1210 -COMMA- denotes ,
T13089 1202-1209 RB denotes Finally
T13088 1189-1200 NN denotes alternative
T13087 1177-1188 JJ denotes interesting
T13086 1174-1176 DT denotes an
T13085 1171-1173 VB denotes be
T13084 1165-1170 MD denotes might
T13083 1161-1164 NN denotes A20
T13082 1158-1160 IN denotes of
T13081 1147-1157 NN denotes inhibitors
T13080 1138-1146 NN denotes compound
T13079 1132-1137 JJ denotes small
T13078 1127-1131 RB denotes Also
T13077 1117-1125 NN denotes approach
T13076 1105-1116 JJ denotes therapeutic
T13075 1099-1104 JJ denotes valid
T13074 1097-1098 DT denotes a
T13073 1094-1096 VB denotes be
T13072 1088-1093 MD denotes might
T13071 1084-1087 NN denotes A20
T13070 1076-1083 IN denotes against
T13069 1070-1075 NN denotes siRNA
T13068 1067-1069 IN denotes of
T13067 1052-1066 NN denotes administration
T13066 1041-1051 JJ denotes intranasal
T13065 1038-1040 IN denotes by
T13064 1029-1037 NN denotes response
T13063 1022-1028 JJ denotes immune
T13062 1012-1021 JJ denotes antiviral
T13061 1008-1011 DT denotes the
T13060 999-1007 VB denotes boosting
T13059 995-998 CC denotes but
T13058 993-994 -COMMA- denotes ,
T13057 983-993 NN denotes components
T13056 979-982 NN denotes IAV
T13055 969-978 VB denotes targeting
T13054 963-968 NN denotes siRNA
T13053 958-962 RB denotes only
T13052 954-957 RB denotes not
T13051 949-953 IN denotes that
T13050 941-948 VB denotes suggest
T13049 933-940 NN denotes results
T13048 929-932 PRP-DOLLAR- denotes Our
T13047 926-927 -RRB- denotes ]
T13046 924-926 CD denotes 83
T13045 923-924 -LRB- denotes [
T13044 914-922 NN denotes optimism
T13043 910-913 CC denotes and
T13042 902-909 NN denotes success
T13041 890-901 JJ denotes significant
T13040 878-889 VB denotes experienced
T13039 874-877 VB denotes has
T13038 872-873 -COMMA- denotes ,
T13037 867-872 NN denotes virus
T13036 857-866 NN denotes influenza
T13035 854-856 TO denotes to
T13034 846-853 VB denotes limited
T13033 842-845 RB denotes not
T13032 838-841 CC denotes but
T13031 836-837 -COMMA- denotes ,
T13030 827-836 VB denotes including
T13029 819-826 NN denotes viruses
T13028 807-818 JJ denotes respiratory
T13027 799-806 IN denotes against
T13026 793-798 NN denotes siRNA
T13025 790-792 IN denotes of
T13024 778-789 NN denotes application
T13023 767-777 JJ denotes intranasal
T13022 765-766 -COMMA- denotes ,
T13021 758-765 JJ denotes general
T13020 755-757 IN denotes in
T13019 750-754 NN denotes RNAi
T13018 747-749 IN denotes of
T13017 734-746 NN denotes applications
T13016 725-733 JJ denotes clinical
T13015 721-724 DT denotes the
T13014 718-720 IN denotes in
T13013 706-717 NN denotes bottlenecks
T13012 700-705 JJ denotes major
T13011 693-699 VB denotes remain
T13010 684-692 NN denotes delivery
T13009 677-683 NN denotes tissue
T13008 673-676 CC denotes and
T13007 661-672 NN denotes specificity
T13006 652-660 IN denotes Although
T13005 639-650 NN denotes replication
T13004 633-638 NN denotes virus
T13003 623-632 NN denotes influenza
T13002 620-622 IN denotes of
T13001 609-619 NN denotes inhibitors
T13000 602-608 JJ denotes potent
T12999 599-601 IN denotes as
T12998 590-598 VB denotes function
T12997 587-589 TO denotes to
T12996 581-586 VB denotes shown
T12995 576-580 VB denotes been
T12994 571-575 VB denotes have
T12993 564-570 NN denotes siRNAs
T12992 555-563 VB denotes designed
T12991 546-554 RB denotes Properly
T12990 537-544 NN denotes regimen
T12989 527-536 JJ denotes antiviral
T12988 520-526 JJ denotes potent
T12987 518-519 DT denotes a
T12986 515-517 IN denotes as
T12985 507-514 VB denotes evolved
T12984 499-506 RB denotes rapidly
T12983 495-498 VB denotes has
T12982 493-494 -COMMA- denotes ,
T12981 492-493 -RRB- denotes )
T12980 487-492 NN denotes siRNA
T12979 486-487 -LRB- denotes (
T12978 482-485 NN denotes RNA
T12977 470-481 VB denotes interfering
T12976 464-469 JJ denotes short
T12975 454-463 JJ denotes synthetic
T12974 451-453 IN denotes by
T12973 441-450 VB denotes triggered
T12972 439-440 -COMMA- denotes ,
T12971 427-439 NN denotes interference
T12970 423-426 NN denotes RNA
T12969 421-422 -COMMA- denotes ,
T12968 416-421 NN denotes years
T12967 409-415 JJ denotes recent
T12966 406-408 IN denotes In
T12965 398-404 NN denotes battle
T12964 391-397 VB denotes ending
T12963 385-390 RB denotes never
T12962 383-384 DT denotes a
T12961 378-382 IN denotes into
T12960 371-377 NN denotes design
T12959 361-370 JJ denotes antiviral
T12958 357-360 CC denotes and
T12957 349-356 NN denotes vaccine
T12956 346-348 IN denotes of
T12955 337-345 NN denotes attempts
T12954 333-336 DT denotes all
T12953 327-332 VB denotes turns
T12952 323-326 NN denotes IAV
T12951 320-322 IN denotes of
T12950 315-319 NN denotes rate
T12949 306-314 NN denotes mutation
T12948 301-305 JJ denotes high
T12947 297-300 DT denotes The
T12946 278-295 JJ denotes immunocompromised
R9458 T12901 T12902 arg1Of Understanding,and
R9459 T12902 T12911 arg2Of and,is
R9460 T12903 T12902 arg2Of controlling,and
R9461 T12905 T12901 arg2Of activation,Understanding
R9462 T12905 T12903 arg2Of activation,controlling
R9463 T12905 T12904 arg1Of activation,the
R9464 T12905 T12906 arg1Of activation,of
R9465 T12910 T12906 arg2Of responses,of
R9466 T12910 T12907 arg1Of responses,innate
R9467 T12910 T12908 arg1Of responses,antiviral
R9468 T12910 T12909 arg1Of responses,immune
R9469 T12914 T12901 arg1Of step,Understanding
R9470 T12914 T12903 arg1Of step,controlling
R9471 T12914 T12911 arg1Of step,is
R9472 T12914 T12912 arg1Of step,an
R9473 T12914 T12913 arg1Of step,important
R9474 T12914 T12915 arg1Of step,toward
R9475 T12917 T12915 arg2Of therapies,toward
R9476 T12917 T12916 arg1Of therapies,novel
R9477 T12920 T12918 arg1Of fifth,About
R9478 T12920 T12919 arg1Of fifth,a
R9479 T12920 T12921 arg1Of fifth,of
R9480 T12920 T12925 arg1Of fifth,is
R9481 T12920 T12926 arg2Of fifth,infected
R9482 T12922 T12923 arg2Of world,'s
R9483 T12924 T12921 arg2Of population,of
R9484 T12924 T12923 arg1Of population,'s
R9485 T12926 T12925 arg2Of infected,is
R9486 T12926 T12929 arg1Of infected,annually
R9487 T12926 T12930 arg1Of infected,","
R9488 T12926 T12931 modOf infected,leading
R9489 T12926 T12937 arg1Of infected,","
R9490 T12926 T12939 arg1Of infected,in
R9491 T12928 T12926 arg1Of IAV,infected
R9492 T12928 T12927 arg2Of IAV,by
R9493 T12931 T12932 arg1Of leading,to
R9494 T12934 T12935 arg1Of morbidity,and
R9495 T12935 T12932 arg2Of and,to
R9496 T12935 T12933 arg1Of and,high
R9497 T12936 T12935 arg2Of mortality,and
R9498 T12939 T12938 arg1Of in,particularly
R9499 T12940 T12939 arg2Of infants,in
R9500 T12940 T12941 arg1Of infants,","
R9501 T12943 T12942 arg1Of elderly,the
R9502 T12943 T12944 arg1Of elderly,and
R9503 T12944 T12941 arg2Of and,","
R9504 T12946 T12944 arg2Of immunocompromised,and
R9505 T12946 T12945 arg1Of immunocompromised,the
R9506 T12950 T12947 arg1Of rate,The
R9507 T12950 T12948 arg1Of rate,high
R9508 T12950 T12949 arg1Of rate,mutation
R9509 T12950 T12951 arg1Of rate,of
R9510 T12950 T12953 arg1Of rate,turns
R9511 T12952 T12951 arg2Of IAV,of
R9512 T12955 T12953 arg2Of attempts,turns
R9513 T12955 T12954 arg1Of attempts,all
R9514 T12955 T12956 arg1Of attempts,of
R9515 T12955 T12961 arg1Of attempts,into
R9516 T12957 T12958 arg1Of vaccine,and
R9517 T12958 T12956 arg2Of and,of
R9518 T12960 T12958 arg2Of design,and
R9519 T12960 T12959 arg1Of design,antiviral
R9520 T12962 T12964 arg1Of a,ending
R9521 T12964 T12961 arg2Of ending,into
R9522 T12964 T12962 arg1Of ending,a
R9523 T12964 T12963 arg1Of ending,never
R9524 T12965 T12964 arg2Of battle,ending
R9525 T12968 T12966 arg2Of years,In
R9526 T12968 T12967 arg1Of years,recent
R9527 T12971 T12970 arg1Of interference,RNA
R9528 T12971 T12972 arg1Of interference,","
R9529 T12971 T12973 arg2Of interference,triggered
R9530 T12971 T12983 arg1Of interference,has
R9531 T12971 T12985 arg1Of interference,evolved
R9532 T12978 T12973 arg1Of RNA,triggered
R9533 T12978 T12974 arg2Of RNA,by
R9534 T12978 T12975 arg1Of RNA,synthetic
R9535 T12978 T12976 arg1Of RNA,short
R9536 T12978 T12977 arg1Of RNA,interfering
R9537 T12978 T12979 arg1Of RNA,(
R9538 T12980 T12979 arg2Of siRNA,(
R9539 T12981 T12979 arg3Of ),(
R9540 T12985 T12966 arg1Of evolved,In
R9541 T12985 T12969 arg1Of evolved,","
R9542 T12985 T12982 arg1Of evolved,","
R9543 T12985 T12983 arg2Of evolved,has
R9544 T12985 T12984 arg1Of evolved,rapidly
R9545 T12985 T12986 arg1Of evolved,as
R9546 T12990 T12986 arg2Of regimen,as
R9547 T12990 T12987 arg1Of regimen,a
R9548 T12990 T12988 arg1Of regimen,potent
R9549 T12990 T12989 arg1Of regimen,antiviral
R9550 T12992 T12991 arg1Of designed,Properly
R9551 T12993 T12992 arg1Of siRNAs,designed
R9552 T12993 T12994 arg1Of siRNAs,have
R9553 T12993 T12995 arg1Of siRNAs,been
R9554 T12993 T12996 arg2Of siRNAs,shown
R9555 T12993 T12998 arg1Of siRNAs,function
R9556 T12996 T12994 arg2Of shown,have
R9557 T12996 T12995 arg2Of shown,been
R9558 T12998 T12996 arg3Of function,shown
R9559 T12998 T12997 arg1Of function,to
R9560 T12998 T12999 arg1Of function,as
R9561 T13001 T12999 arg2Of inhibitors,as
R9562 T13001 T13000 arg1Of inhibitors,potent
R9563 T13001 T13002 arg1Of inhibitors,of
R9564 T13005 T13002 arg2Of replication,of
R9565 T13005 T13003 arg1Of replication,influenza
R9566 T13005 T13004 arg1Of replication,virus
R9567 T13007 T13008 arg1Of specificity,and
R9568 T13008 T13011 arg1Of and,remain
R9569 T13010 T13008 arg2Of delivery,and
R9570 T13010 T13009 arg1Of delivery,tissue
R9571 T13011 T13006 arg2Of remain,Although
R9572 T13011 T13014 arg1Of remain,in
R9573 T13011 T13020 arg1Of remain,in
R9574 T13013 T13011 arg2Of bottlenecks,remain
R9575 T13013 T13012 arg1Of bottlenecks,major
R9576 T13017 T13014 arg2Of applications,in
R9577 T13017 T13015 arg1Of applications,the
R9578 T13017 T13016 arg1Of applications,clinical
R9579 T13017 T13018 arg1Of applications,of
R9580 T13019 T13018 arg2Of RNAi,of
R9581 T13021 T13020 arg2Of general,in
R9582 T13024 T13023 arg1Of application,intranasal
R9583 T13024 T13025 arg1Of application,of
R9584 T13024 T13027 arg1Of application,against
R9585 T13024 T13034 arg2Of application,limited
R9586 T13024 T13039 arg1Of application,has
R9587 T13024 T13040 arg1Of application,experienced
R9588 T13026 T13025 arg2Of siRNA,of
R9589 T13029 T13027 arg2Of viruses,against
R9590 T13029 T13028 arg1Of viruses,respiratory
R9591 T13029 T13030 arg1Of viruses,including
R9592 T13030 T13032 arg1Of including,but
R9593 T13032 T13031 arg1Of but,","
R9594 T13032 T13033 arg1Of but,not
R9595 T13034 T13035 arg1Of limited,to
R9596 T13037 T13035 arg2Of virus,to
R9597 T13037 T13036 arg1Of virus,influenza
R9598 T13040 T13006 arg1Of experienced,Although
R9599 T13040 T13022 arg1Of experienced,","
R9600 T13040 T13038 arg1Of experienced,","
R9601 T13040 T13039 arg2Of experienced,has
R9602 T13042 T13041 arg1Of success,significant
R9603 T13042 T13043 arg1Of success,and
R9604 T13043 T13040 arg2Of and,experienced
R9605 T13044 T13043 arg2Of optimism,and
R9606 T13044 T13045 arg1Of optimism,[
R9607 T13046 T13045 arg2Of 83,[
R9608 T13047 T13045 arg3Of ],[
R9609 T13049 T13048 arg1Of results,Our
R9610 T13049 T13050 arg1Of results,suggest
R9611 T13053 T13052 arg1Of only,not
R9612 T13054 T13053 arg1Of siRNA,only
R9613 T13054 T13055 arg1Of siRNA,targeting
R9614 T13054 T13060 arg1Of siRNA,boosting
R9615 T13054 T13072 arg1Of siRNA,might
R9616 T13054 T13073 arg1Of siRNA,be
R9617 T13055 T13059 arg1Of targeting,but
R9618 T13057 T13055 arg2Of components,targeting
R9619 T13057 T13056 arg1Of components,IAV
R9620 T13059 T13058 arg1Of but,","
R9621 T13060 T13059 arg2Of boosting,but
R9622 T13064 T13060 arg2Of response,boosting
R9623 T13064 T13061 arg1Of response,the
R9624 T13064 T13062 arg1Of response,antiviral
R9625 T13064 T13063 arg1Of response,immune
R9626 T13064 T13065 arg1Of response,by
R9627 T13067 T13065 arg2Of administration,by
R9628 T13067 T13066 arg1Of administration,intranasal
R9629 T13067 T13068 arg1Of administration,of
R9630 T13067 T13070 arg1Of administration,against
R9631 T13069 T13068 arg2Of siRNA,of
R9632 T13071 T13070 arg2Of A20,against
R9633 T13073 T13050 arg2Of be,suggest
R9634 T13073 T13051 arg1Of be,that
R9635 T13073 T13072 arg2Of be,might
R9636 T13076 T13075 arg1Of therapeutic,valid
R9637 T13077 T13073 arg2Of approach,be
R9638 T13077 T13074 arg1Of approach,a
R9639 T13077 T13076 arg1Of approach,therapeutic
R9640 T13079 T13078 arg1Of small,Also
R9641 T13081 T13079 arg1Of inhibitors,small
R9642 T13081 T13080 arg1Of inhibitors,compound
R9643 T13081 T13082 arg1Of inhibitors,of
R9644 T13081 T13084 arg1Of inhibitors,might
R9645 T13081 T13085 arg1Of inhibitors,be
R9646 T13083 T13082 arg2Of A20,of
R9647 T13085 T13084 arg2Of be,might
R9648 T13088 T13085 arg2Of alternative,be
R9649 T13088 T13086 arg1Of alternative,an
R9650 T13088 T13087 arg1Of alternative,interesting
R9651 T13092 T13091 arg1Of targeting,similar
R9652 T13092 T13093 arg1Of targeting,of
R9653 T13092 T13095 arg1Of targeting,might
R9654 T13092 T13096 arg1Of targeting,be
R9655 T13092 T13097 arg1Of targeting,of
R9656 T13094 T13093 arg2Of A20,of
R9657 T13096 T13089 arg1Of be,Finally
R9658 T13096 T13090 arg1Of be,","
R9659 T13096 T13095 arg2Of be,might
R9660 T13097 T13096 arg2Of of,be
R9661 T13098 T13097 arg2Of interest,of
R9662 T13098 T13099 arg1Of interest,in
R9663 T13101 T13099 arg2Of battle,in
R9664 T13101 T13100 arg1Of battle,the
R9665 T13101 T13102 arg1Of battle,against
R9666 T13105 T13102 arg2Of infections,against
R9667 T13105 T13103 arg1Of infections,other
R9668 T13105 T13104 arg1Of infections,viral
R9669 T13105 T13106 arg1Of infections,including
R9670 T13107 T13108 arg1Of RSV,and
R9671 T13108 T13106 arg2Of and,including
R9672 T13110 T13108 arg2Of coronavirus,and
R9673 T13110 T13109 arg1Of coronavirus,SARS

bionlp-st-ge-2016-uniprot

Id Subject Object Predicate Lexical cue
T14277 1232-1235 http://www.uniprot.org/uniprot/P21580 denotes A20
T14276 1161-1164 http://www.uniprot.org/uniprot/P21580 denotes A20
T14275 1084-1087 http://www.uniprot.org/uniprot/P21580 denotes A20

UBERON-AE

Id Subject Object Predicate Lexical cue
T11702 677-683 http://purl.obolibrary.org/obo/UBERON_0000479 denotes tissue

GO-BP

Id Subject Object Predicate Lexical cue
T11904 750-754 http://purl.obolibrary.org/obo/GO_0016246 denotes RNAi
T11903 423-439 http://purl.obolibrary.org/obo/GO_0016246 denotes RNA interference
T11877 1285-1301 http://purl.obolibrary.org/obo/GO_0016032 denotes viral infections
T11870 1022-1037 http://purl.obolibrary.org/obo/GO_0006955 denotes immune response

sentences

Id Subject Object Predicate Lexical cue
T11740 1202-1337 Sentence denotes Finally, similar targeting of A20 might be of interest in the battle against other viral infections including RSV and SARS coronavirus.
T11739 1127-1201 Sentence denotes Also small compound inhibitors of A20 might be an interesting alternative.
T11738 929-1126 Sentence denotes Our results suggest that not only siRNA targeting IAV components, but boosting the antiviral immune response by intranasal administration of siRNA against A20 might be a valid therapeutic approach.
T11737 652-928 Sentence denotes Although specificity and tissue delivery remain major bottlenecks in the clinical applications of RNAi in general, intranasal application of siRNA against respiratory viruses including, but not limited to influenza virus, has experienced significant success and optimism [83].
T11736 546-651 Sentence denotes Properly designed siRNAs have been shown to function as potent inhibitors of influenza virus replication.
T11735 406-545 Sentence denotes In recent years, RNA interference, triggered by synthetic short interfering RNA (siRNA), has rapidly evolved as a potent antiviral regimen.
T11734 297-405 Sentence denotes The high mutation rate of IAV turns all attempts of vaccine and antiviral design into a never ending battle.
T11733 127-296 Sentence denotes About a fifth of world's population is infected by IAV annually, leading to high morbidity and mortality, particularly in infants, the elderly and the immunocompromised.
T11732 0-126 Sentence denotes Understanding and controlling the activation of innate antiviral immune responses is an important step toward novel therapies.
T186 0-126 Sentence denotes Understanding and controlling the activation of innate antiviral immune responses is an important step toward novel therapies.
T187 127-296 Sentence denotes About a fifth of world's population is infected by IAV annually, leading to high morbidity and mortality, particularly in infants, the elderly and the immunocompromised.
T188 297-405 Sentence denotes The high mutation rate of IAV turns all attempts of vaccine and antiviral design into a never ending battle.
T189 406-545 Sentence denotes In recent years, RNA interference, triggered by synthetic short interfering RNA (siRNA), has rapidly evolved as a potent antiviral regimen.
T190 546-651 Sentence denotes Properly designed siRNAs have been shown to function as potent inhibitors of influenza virus replication.
T191 652-928 Sentence denotes Although specificity and tissue delivery remain major bottlenecks in the clinical applications of RNAi in general, intranasal application of siRNA against respiratory viruses including, but not limited to influenza virus, has experienced significant success and optimism [83].
T192 929-1126 Sentence denotes Our results suggest that not only siRNA targeting IAV components, but boosting the antiviral immune response by intranasal administration of siRNA against A20 might be a valid therapeutic approach.
T193 1127-1201 Sentence denotes Also small compound inhibitors of A20 might be an interesting alternative.
T194 1202-1337 Sentence denotes Finally, similar targeting of A20 might be of interest in the battle against other viral infections including RSV and SARS coronavirus.

ICD10

Id Subject Object Predicate Lexical cue
T11908 1279-1301 http://purl.bioontology.org/ontology/ICD10/B34.8 denotes other viral infections
T11907 684-692 http://purl.bioontology.org/ontology/ICD10/O80-O84.9 denotes delivery
T11906 1285-1301 http://purl.bioontology.org/ontology/ICD10/B34.9 denotes viral infections

bionlp-st-ge-2016-test-ihmc

Id Subject Object Predicate Lexical cue
T14687 527-536 Entity denotes antiviral
T14685 349-356 Entity denotes vaccine
T14674 482-494 Protein denotes RNA (siRNA),
T14672 1229-1235 Protein denotes of A20
T14664 1008-1021 Entity denotes the antiviral
T14657 1132-1164 Entity denotes small compound inhibitors of A20
T14646 361-370 Entity denotes antiviral
T14641 45-81 Entity denotes of innate antiviral immune responses
T14635 1161-1164 Protein denotes A20
T14634 1084-1087 Protein denotes A20
T14625 1320-1324 Protein denotes SARS
T14611 602-650 Entity denotes potent inhibitors of influenza virus replication

bionlp-st-ge-2016-spacy-parsed

Id Subject Object Predicate Lexical cue
T14245 1242-1244 VB denotes be
T14244 1236-1241 MD denotes might
T14243 1232-1235 NNP denotes A20
T14242 1229-1231 IN denotes of
T14241 1219-1228 VBG denotes targeting
T14240 1211-1218 JJ denotes similar
T14239 1209-1210 , denotes ,
T14238 1202-1209 RB denotes Finally
T14237 1200-1201 . denotes .
T14236 1189-1200 NN denotes alternative
T14235 1177-1188 JJ denotes interesting
T14234 1174-1176 DT denotes an
T14233 1171-1173 VB denotes be
T14232 1165-1170 MD denotes might
T14231 1161-1164 NNP denotes A20
T14230 1158-1160 IN denotes of
T14229 1147-1157 NNS denotes inhibitors
T14228 1138-1146 NN denotes compound
T14227 1132-1137 JJ denotes small
T14226 1127-1131 RB denotes Also
T14225 1125-1126 . denotes .
T14224 1117-1125 NN denotes approach
T14223 1105-1116 JJ denotes therapeutic
T14222 1099-1104 JJ denotes valid
T14221 1097-1098 DT denotes a
T14220 1094-1096 VB denotes be
T14219 1088-1093 MD denotes might
T14218 1084-1087 NNP denotes A20
T14217 1076-1083 IN denotes against
T14216 1070-1075 NN denotes siRNA
T14215 1067-1069 IN denotes of
T14214 1052-1066 NN denotes administration
T14213 1041-1051 JJ denotes intranasal
T14212 1038-1040 IN denotes by
T14211 1029-1037 NN denotes response
T14210 1022-1028 JJ denotes immune
T14209 1012-1021 JJ denotes antiviral
T14208 1008-1011 DT denotes the
T14207 999-1007 VBG denotes boosting
T14206 995-998 CC denotes but
T14205 993-994 , denotes ,
T14204 983-993 NNS denotes components
T14203 979-982 NNP denotes IAV
T14202 969-978 VBG denotes targeting
T14201 963-968 JJ denotes siRNA
T14200 958-962 RB denotes only
T14199 954-957 RB denotes not
T14198 949-953 IN denotes that
T14197 941-948 VBP denotes suggest
T14196 933-940 NNS denotes results
T14195 929-932 PRP$ denotes Our
T14194 927-928 . denotes .
T14193 926-927 NNP denotes ]
T14192 924-926 CD denotes 83
T14191 923-924 NNP denotes [
T14190 914-922 NN denotes optimism
T14189 910-913 CC denotes and
T14188 902-909 NN denotes success
T14187 890-901 JJ denotes significant
T14186 878-889 VBN denotes experienced
T14185 874-877 VBZ denotes has
T14184 872-873 , denotes ,
T14183 867-872 NN denotes virus
T14182 857-866 VB denotes influenza
T14181 854-856 TO denotes to
T14180 846-853 VBN denotes limited
T14179 842-845 RB denotes not
T14178 838-841 CC denotes but
T14177 836-837 , denotes ,
T14176 827-836 VBG denotes including
T14175 819-826 NNS denotes viruses
T14174 807-818 JJ denotes respiratory
T14173 799-806 IN denotes against
T14172 793-798 NN denotes siRNA
T14171 790-792 IN denotes of
T14170 778-789 NN denotes application
T14169 767-777 JJ denotes intranasal
T14168 765-766 , denotes ,
T14167 758-765 JJ denotes general
T14166 755-757 IN denotes in
T14165 750-754 NNS denotes RNAi
T14164 747-749 IN denotes of
T14163 734-746 NNS denotes applications
T14162 725-733 JJ denotes clinical
T14161 721-724 DT denotes the
T14160 718-720 IN denotes in
T14159 706-717 NNS denotes bottlenecks
T14158 700-705 JJ denotes major
T14157 693-699 VBP denotes remain
T14156 684-692 NN denotes delivery
T14155 677-683 NN denotes tissue
T14154 673-676 CC denotes and
T14153 661-672 NN denotes specificity
T14152 652-660 IN denotes Although
T14151 650-651 . denotes .
T14150 639-650 NN denotes replication
T14149 633-638 NN denotes virus
T14148 623-632 NN denotes influenza
T14147 620-622 IN denotes of
T14146 609-619 NNS denotes inhibitors
T14145 602-608 JJ denotes potent
T14144 599-601 IN denotes as
T14143 590-598 VB denotes function
T14142 587-589 TO denotes to
T14141 581-586 VBN denotes shown
T14140 576-580 VBN denotes been
T14139 571-575 VBP denotes have
T14138 564-570 NNS denotes siRNAs
T14137 555-563 VBN denotes designed
T14136 546-554 RB denotes Properly
T14135 544-545 . denotes .
T14134 537-544 NN denotes regimen
T14133 527-536 JJ denotes antiviral
T14132 520-526 JJ denotes potent
T14131 518-519 DT denotes a
T14130 515-517 IN denotes as
T14129 507-514 VBN denotes evolved
T14128 499-506 RB denotes rapidly
T14127 495-498 VBZ denotes has
T14126 493-494 , denotes ,
T14125 492-493 -RRB- denotes )
T14124 487-492 NNP denotes siRNA
T14123 486-487 -LRB- denotes (
T14122 482-485 NNP denotes RNA
T14121 470-481 VBG denotes interfering
T14120 464-469 JJ denotes short
T14119 454-463 JJ denotes synthetic
T14118 451-453 IN denotes by
T14117 441-450 VBN denotes triggered
T14116 439-440 , denotes ,
T14115 427-439 NN denotes interference
T14114 423-426 NNP denotes RNA
T14113 421-422 , denotes ,
T14112 416-421 NNS denotes years
T14111 409-415 JJ denotes recent
T14110 406-408 IN denotes In
T14109 404-405 . denotes .
T14108 398-404 NN denotes battle
T14107 391-397 VBG denotes ending
T14106 385-390 RB denotes never
T14105 383-384 DT denotes a
T14104 378-382 IN denotes into
T14103 371-377 NN denotes design
T14102 361-370 JJ denotes antiviral
T14101 357-360 CC denotes and
T14100 349-356 NN denotes vaccine
T14099 346-348 IN denotes of
T14098 337-345 NNS denotes attempts
T14097 333-336 DT denotes all
T14096 327-332 VBZ denotes turns
T14095 323-326 NNP denotes IAV
T14094 320-322 IN denotes of
T14093 315-319 NN denotes rate
T14092 306-314 NN denotes mutation
T14091 301-305 JJ denotes high
T14090 297-300 DT denotes The
T14089 295-296 . denotes .
T14088 278-295 JJ denotes immunocompromised
T14087 274-277 DT denotes the
T14086 270-273 CC denotes and
T14085 262-269 JJ denotes elderly
T14084 258-261 DT denotes the
T14083 256-257 , denotes ,
T14082 249-256 NNS denotes infants
T14081 246-248 IN denotes in
T14080 233-245 RB denotes particularly
T14079 231-232 , denotes ,
T14078 222-231 NN denotes mortality
T14077 218-221 CC denotes and
T14076 208-217 NN denotes morbidity
T14075 203-207 JJ denotes high
T14074 200-202 TO denotes to
T14073 192-199 VBG denotes leading
T14072 190-191 , denotes ,
T14071 182-190 RB denotes annually
T14070 178-181 NNP denotes IAV
T14069 175-177 IN denotes by
T14068 166-174 VBN denotes infected
T14067 163-165 VBZ denotes is
T14066 152-162 NN denotes population
T14065 149-151 POS denotes 's
T14064 144-149 NN denotes world
T14063 141-143 IN denotes of
T14062 135-140 NN denotes fifth
T14061 133-134 DT denotes a
T14060 127-132 IN denotes About
T14059 125-126 . denotes .
T14058 116-125 NNS denotes therapies
T14057 110-115 NN denotes novel
T14056 103-109 IN denotes toward
T14055 98-102 NN denotes step
T14054 88-97 JJ denotes important
T14053 85-87 DT denotes an
T14052 82-84 VBZ denotes is
T14051 72-81 NNS denotes responses
T14050 65-71 JJ denotes immune
T14049 55-64 JJ denotes antiviral
T14048 48-54 NN denotes innate
T14047 45-47 IN denotes of
T14046 34-44 NN denotes activation
T14045 30-33 DT denotes the
T14044 18-29 VBG denotes controlling
T14043 14-17 CC denotes and
T14042 0-13 NN denotes Understanding
T14260 1336-1337 . denotes .
T14259 1325-1336 NN denotes coronavirus
T14258 1320-1324 NNP denotes SARS
T14257 1316-1319 CC denotes and
T14256 1312-1315 NNP denotes RSV
T14255 1302-1311 VBG denotes including
T14254 1291-1301 NNS denotes infections
T14253 1285-1290 JJ denotes viral
T14252 1279-1284 JJ denotes other
T14251 1271-1278 IN denotes against
T14250 1264-1270 NN denotes battle
T14249 1260-1263 DT denotes the
T14248 1257-1259 IN denotes in
T14247 1248-1256 NN denotes interest
T14246 1245-1247 IN denotes of
R10569 T14048 T14051 amod innate,responses
R10570 T14049 T14051 amod antiviral,responses
R10572 T14050 T14051 amod immune,responses
R10584 T14058 T14056 pobj therapies,toward
R10585 T14059 T14052 punct .,is
R10587 T14060 T14062 advmod About,fifth
R10588 T14061 T14062 det a,fifth
R10589 T14062 T14068 nsubjpass fifth,infected
R10591 T14063 T14062 prep of,fifth
R10592 T14064 T14066 poss world,population
R10594 T14065 T14064 case 's,world
R10595 T14066 T14063 pobj population,of
R10596 T14067 T14068 auxpass is,infected
R10597 T14068 T14068 ROOT infected,infected
R10599 T14069 T14068 agent by,infected
R10600 T14070 T14069 pobj IAV,by
R10602 T14071 T14068 advmod annually,infected
R10603 T14072 T14068 punct ",",infected
R10604 T14073 T14068 advcl leading,infected
R10608 T14074 T14073 prep to,leading
R10610 T14075 T14076 amod high,morbidity
R10612 T14076 T14074 pobj morbidity,to
R10613 T14077 T14076 cc and,morbidity
R10614 T14078 T14076 conj mortality,morbidity
R10616 T14079 T14068 punct ",",infected
R10617 T14080 T14081 advmod particularly,in
R10618 T14081 T14068 prep in,infected
R10620 T14082 T14081 pobj infants,in
R10621 T14083 T14068 punct ",",infected
R10622 T14084 T14085 det the,elderly
R10624 T14085 T14068 conj elderly,infected
R10625 T14086 T14085 cc and,elderly
R10626 T14087 T14088 det the,immunocompromised
R10628 T14088 T14085 conj immunocompromised,elderly
R10629 T14089 T14068 punct .,infected
R10630 T14090 T14093 det The,rate
R10632 T14091 T14093 amod high,rate
R10633 T14092 T14093 compound mutation,rate
R10634 T14093 T14096 nsubj rate,turns
R10635 T14094 T14093 prep of,rate
R10636 T14095 T14094 pobj IAV,of
R10638 T14096 T14096 ROOT turns,turns
R10639 T14097 T14098 det all,attempts
R10640 T14098 T14096 dobj attempts,turns
R10642 T14099 T14098 prep of,attempts
R10643 T14100 T14099 pobj vaccine,of
R10644 T14101 T14100 cc and,vaccine
R10646 T14102 T14103 amod antiviral,design
R10647 T14103 T14100 conj design,vaccine
R10648 T14104 T14096 prep into,turns
R10650 T14105 T14108 det a,battle
R10651 T14106 T14107 neg never,ending
R10652 T14107 T14108 amod ending,battle
R10654 T14108 T14104 pobj battle,into
R10655 T14109 T14096 punct .,turns
R10656 T14110 T14129 prep In,evolved
R10658 T14111 T14112 amod recent,years
R10659 T14112 T14110 pobj years,In
R10660 T14113 T14129 punct ",",evolved
R10661 T14114 T14115 compound RNA,interference
R10663 T14115 T14129 nsubj interference,evolved
R10664 T14116 T14117 punct ",",triggered
R10665 T14117 T14115 acl triggered,interference
R10667 T14118 T14117 agent by,triggered
R10668 T14119 T14122 amod synthetic,RNA
R10669 T14120 T14121 amod short,interfering
R10671 T14121 T14122 amod interfering,RNA
R10672 T14122 T14118 pobj RNA,by
R10691 T14135 T14129 punct .,evolved
R10692 T14136 T14137 advmod Properly,designed
R10694 T14137 T14138 amod designed,siRNAs
R10695 T14138 T14141 nsubjpass siRNAs,shown
R10696 T14042 T14052 nsubj Understanding,is
R10697 T14139 T14141 aux have,shown
R10698 T14140 T14141 auxpass been,shown
R10699 T14141 T14141 ROOT shown,shown
R10700 T14043 T14042 cc and,Understanding
R10701 T14142 T14143 aux to,function
R10702 T14143 T14141 xcomp function,shown
R10703 T14144 T14143 prep as,function
R10704 T14044 T14042 conj controlling,Understanding
R10705 T14045 T14046 det the,activation
R10706 T14046 T14044 dobj activation,controlling
R10707 T14047 T14046 prep of,activation
R10708 T14145 T14146 amod potent,inhibitors
R10709 T14146 T14144 pobj inhibitors,as
R10710 T14147 T14146 prep of,inhibitors
R10711 T14242 T14241 prep of,targeting
R10712 T14148 T14149 compound influenza,virus
R10713 T14243 T14242 pobj A20,of
R10714 T14149 T14150 compound virus,replication
R10715 T14150 T14147 pobj replication,of
R10716 T14151 T14141 punct .,shown
R10717 T14244 T14245 aux might,be
R10718 T14152 T14157 mark Although,remain
R10719 T14153 T14157 nsubj specificity,remain
R10720 T14154 T14153 cc and,specificity
R10721 T14245 T14245 ROOT be,be
R10722 T14155 T14156 compound tissue,delivery
R10723 T14156 T14153 conj delivery,specificity
R10724 T14157 T14186 advcl remain,experienced
R10725 T14246 T14245 prep of,be
R10726 T14158 T14159 amod major,bottlenecks
R10727 T14159 T14157 dobj bottlenecks,remain
R10728 T14160 T14157 prep in,remain
R10729 T14247 T14246 pobj interest,of
R10730 T14161 T14163 det the,applications
R10731 T14162 T14163 amod clinical,applications
R10732 T14248 T14247 prep in,interest
R10733 T14163 T14160 pobj applications,in
R10734 T14164 T14163 prep of,applications
R10735 T14165 T14164 pobj RNAi,of
R10736 T14166 T14165 prep in,RNAi
R10737 T14167 T14166 amod general,in
R10738 T14168 T14165 punct ",",RNAi
R10739 T14169 T14170 amod intranasal,application
R10740 T14249 T14250 det the,battle
R10741 T14170 T14157 npadvmod application,remain
R10742 T14171 T14170 prep of,application
R10743 T14250 T14248 pobj battle,in
R10744 T14172 T14171 pobj siRNA,of
R10745 T14251 T14250 prep against,battle
R10746 T14173 T14172 prep against,siRNA
R10747 T14174 T14175 amod respiratory,viruses
R10748 T14175 T14173 pobj viruses,against
R10749 T14176 T14175 prep including,viruses
R10750 T14252 T14254 amod other,infections
R10751 T14177 T14170 punct ",",application
R10752 T14178 T14170 cc but,application
R10753 T14179 T14180 neg not,limited
R10754 T14253 T14254 amod viral,infections
R10755 T14180 T14183 amod limited,virus
R10756 T14181 T14182 aux to,influenza
R10757 T14182 T14183 compound influenza,virus
R10758 T14254 T14251 pobj infections,against
R10759 T14183 T14170 conj virus,application
R10760 T14184 T14186 punct ",",experienced
R10761 T14185 T14186 aux has,experienced
R10762 T14255 T14254 prep including,infections
R10763 T14186 T14186 ROOT experienced,experienced
R10764 T14187 T14188 amod significant,success
R10765 T14188 T14186 dobj success,experienced
R10766 T14189 T14188 cc and,success
R10767 T14256 T14255 pobj RSV,including
R10768 T14190 T14188 conj optimism,success
R10769 T14191 T14193 nmod [,]
R10770 T14192 T14193 nummod 83,]
R10771 T14257 T14256 cc and,RSV
R10772 T14193 T14190 appos ],optimism
R10773 T14194 T14186 punct .,experienced
R10774 T14195 T14196 poss Our,results
R10775 T14258 T14259 compound SARS,coronavirus
R10776 T14196 T14197 nsubj results,suggest
R10777 T14197 T14197 ROOT suggest,suggest
R10778 T14198 T14220 mark that,be
R10779 T14259 T14256 conj coronavirus,RSV
R10780 T14199 T14220 preconj not,be
R10781 T14200 T14199 advmod only,not
R10782 T14201 T14220 nsubj siRNA,be
R10783 T14260 T14245 punct .,be
R10794 T14211 T14207 dobj response,boosting
R10795 T14212 T14211 prep by,response
R10796 T14213 T14214 amod intranasal,administration
R10797 T14214 T14212 pobj administration,by
R10798 T14215 T14214 prep of,administration
R10799 T14216 T14215 pobj siRNA,of
R10800 T14217 T14216 prep against,siRNA
R10801 T14218 T14217 pobj A20,against
R10802 T14219 T14220 aux might,be
R10803 T14220 T14197 ccomp be,suggest
R10804 T14221 T14224 det a,approach
R10805 T14222 T14224 amod valid,approach
R10806 T14223 T14224 amod therapeutic,approach
R10807 T14224 T14220 attr approach,be
R10808 T14225 T14197 punct .,suggest
R10809 T14226 T14233 advmod Also,be
R10810 T14227 T14229 amod small,inhibitors
R10811 T14228 T14229 compound compound,inhibitors
R10812 T14229 T14233 nsubj inhibitors,be
R10813 T14230 T14229 prep of,inhibitors
R10814 T14231 T14230 pobj A20,of
R10815 T14232 T14233 aux might,be
R10816 T14233 T14233 ROOT be,be
R10817 T14234 T14236 det an,alternative
R10818 T14235 T14236 amod interesting,alternative
R10819 T14236 T14233 attr alternative,be
R10820 T14237 T14233 punct .,be
R10821 T14238 T14241 advmod Finally,targeting
R10823 T14239 T14241 punct ",",targeting
R10824 T14240 T14241 amod similar,targeting
R10825 T14241 T14245 nsubj targeting,be
R10575 T14051 T14047 pobj responses,of
R10576 T14052 T14052 ROOT is,is
R10578 T14053 T14055 det an,step
R10579 T14054 T14055 amod important,step
R10581 T14055 T14052 attr step,is
R10582 T14056 T14055 prep toward,step
R10583 T14057 T14058 compound novel,therapies
R10675 T14123 T14122 punct (,RNA
R10676 T14124 T14122 appos siRNA,RNA
R10678 T14125 T14122 punct ),RNA
R10679 T14126 T14129 punct ",",evolved
R10680 T14127 T14129 aux has,evolved
R10682 T14128 T14129 advmod rapidly,evolved
R10684 T14129 T14129 ROOT evolved,evolved
R10685 T14130 T14129 prep as,evolved
R10686 T14131 T14134 det a,regimen
R10687 T14132 T14134 amod potent,regimen
R10689 T14133 T14134 amod antiviral,regimen
R10690 T14134 T14130 pobj regimen,as
R10793 T14210 T14211 amod immune,response
R10784 T14202 T14201 acl targeting,siRNA
R10785 T14203 T14204 compound IAV,components
R10787 T14204 T14202 dobj components,targeting
R10788 T14205 T14202 punct ",",targeting
R10789 T14206 T14202 cc but,targeting
R10790 T14207 T14202 conj boosting,targeting
R10791 T14208 T14211 det the,response
R10792 T14209 T14211 amod antiviral,response

bionlp-st-ge-2016-test-tees

Id Subject Object Predicate Lexical cue
T14490 1219-1228 Localization denotes targeting
T14489 1320-1336 Protein denotes SARS coronavirus
T14488 1232-1235 Protein denotes A20
T14487 1084-1087 Protein denotes A20
R10906 T14488 T14490 themeOf A20,targeting

testone

Id Subject Object Predicate Lexical cue
T11613 1147-1157 Negative_regulation denotes inhibitors